COVID-19 (Coronavirus) Update:


KOMIPHARM continues to conduct research and provide medicines around the world.


12 May 2020

Safeguarding our people, patients and business partners remains our top priority. As the COVID-19 pandemic evolves, KOMIPHARM continues to provide medicines to clinical trials around the world. In addition, we have taken measures to support the health and well-being of our people. We continue to closely monitor the outbreak to minimize business impact.

Our People:  

We have taken numerous steps to help ensure the health and safety of our workforce. This includes restricting international travel until further notice and encouraging employees to utilise various communication technologies to minimize business disruption.

Our Patients & Products:  

KOMIPHARM continues to provide an uninterrupted supply of our medicines around the world for ongoing COVID-19 and cancer research. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.

We have ongoing clinical trials at investigational sites worldwide and remain in close contact with researchers who are involved in this important work to evaluate promising new medicines, discussing the best ways to manage patient visits and follow-up appointments.

We are working with contract research organizations and authorities around the world in the effort to develop a COVID-19 treatment.

Our efforts to help battle the Coronavirus pandemic

KOMIPHARM has projects underway for developing a treatment for COVID-19.

KOMIPHARM has partnered with global Contract Research Organizations to fast track clinical trials to develop a treatment for COVID-19 patients in the European Union including OPIS CRO, a European company, which provides premium clinical trial management for multi-country clinical trials. KOMIPHARM is also preparing clinical projects for entry into Asia and the USA.